We describe an unusual case of a patient with eosinophilic pleural effusion (EPE) associated with long-term propylthiouracil (PTU) administration. A 43-year-old woman was admitted to our hospital after complaining of chest pain. She had had Graves’ disease, which had been treated with PTU for 11 years. Right-sided pleural effusion was detected and the result of thoracentesis confirmed an EPE. The patient’s detailed medical evaluation failed to reveal any other cause of EPE. PTU was terminated since it was thought to be the cause. Despite withdrawal of the medication, however, the pleural effusion persisted for 6 weeks, and steroid therapy was planned for 15 days in decreasing dosages. During the control visit 10 days after the initiation of steroid therapy, no pleural effusion was observed, and the steroid was discontinued. Rechallenge with PTU produced recurrent pleural effusion. Therapy with PTU was again terminated, and treatment with methimazole and a brief course of low-dose corticosteroids were begun. Chest radiography revealed disappearance of the effusion within 10 days and it did not recur during a 1-year follow-up. To our knowledge, there is only 1 other case in the English-language literature describing EPE caused by PTU. Our report is of particular importance because it describes the development of that disorder in the 11th year of PTU treatment. It also shows that steroid therapy can be effective in treating drug-induced EPE.

Keywords:
Eosinophilic pleural effusion, Thionamide, Propylthiouracil, Corticosteroid
1.
Cooper DS: Antithyroid drugs. N Engl J Med 2005;352:905–917.
2.
Miyazono K, Okazaki T, Uchida S, Totsuka Y, Matsumoto T, Ogata E, Terakawa K, Kurihara N, Takeda T: Propylthiouracil-induced diffuse interstitial pneumonitis. Arch Intern Med 1984;144:1764–1765.
3.
Cassorla FG, Finegold DN, Parks JS, Tenore A, Thawerani H, Baker L: Vasculitis, pulmonary cavitation, and anemia during antithyroid drug therapy. Am J Dis Child 1983;137:118–122.
4.
Pirot AL, Goldsmith D, Pascasio J, Beck SA: Pulmonary capillaritis with hemorrhage due to propylthiouracil therapy in a child. Pediatr Pulmonol 2005;39:88–92.
5.
Middleton KL, Santella R, Couser JI Jr: Eosinophilic pleuritis due to propylthiouracil. Chest 1993;103:955–956.
6.
Rubins JB, Rubins HB: Etiology and prognostic significance of eosinophilic pleural effusions. Chest 1996;110:1271–1274.
7.
Kuhn M, Fitting JW, Leuenberger P: Probability of malignancy in pleural fluid eosinophilia. Chest 1989;96:992–994.
8.
Adelman M, Albelda SM, Gottlieb J, Haponik EF: Diagnostic utility of pleural fluid eosinophilia. Am J Med 1984;77:915–920.
9.
Kalomenidis I, Light RW: Eosinophilic pleural effusions. Curr Opin Pulm Med 2003;9:254–260.
10.
Martinez-Garcia MA, Cases-Viedma E, Cordero-Rodriguez PJ, Hidalgo-Ramirez M, Perpina-Tordera M, Sanchis-Moret F, Sanchis-Aldas JL: Diagnostic utility of eosinophils in the pleural fluid. Eur Respir J 2000;15:166–169.
11.
Mahoney JM, Bachtel MD: Pleural effusion associated with chronic dantrolene administration. Ann Pharmacother 1994;28:587–589.
12.
Felz MW, Haviland-Foley DJ: Eosinophilic pleural effusion due to dantrolene: resolution with steroid therapy. South Med J 2001;94:502–504.
13.
Behnia M, Dowdeswell I, Vakili S: Pleural fluid and serum eosinophilia: association with fluoxetine hydrochloride. South Med J 2000;93:611–613.
14.
Yoshida H, Hasegawa R, Hayashi H, Irie Y: Imidapril-induced eosinophilic pleurisy: case report and review of the literature. Respiration 2005;72:423–426.
15.
Kravetz JD, Federman DG: Valproic acid-induced eosinophilic pleural effusion. South Med J 2003;96:803–806.
16.
Tzanakis N, Bouros D, Siafakas N: Eosinophilic pleural effusion due to gliclazide. Respir Med 2000;94:94.
17.
Milleron BJ, Valcke J, Akoun GM, Mayaud CM: Isotretinoin-related eosinophilic pleural effusion. Chest 1996;110:1128.
18.
Bunker CB, Sheron N, Maurice PD, Kocjan G, Johnson NM, Dowd PM: Isotretinoin and eosinophilic pleural effusion. Lancet 1989;1:435–436.
19.
Strong DH, Westcott JY, Biller JA, Morrison JL, Effors RM, Maloney JP: Eosinophilic ‘empyema’ associated with crack cocaine use. Thorax 2003;58:823–824.
20.
Light RW: Pleural Diseases, ed 4. Baltimore, Lippincott Williams & Wilkins, 2001, pp 48–50.
21.
Pettersson T, Riska H, Sutinen S, Klockars M, Peterson C: High concentrations of eosinophil cationic protein and eosinophil protein X in eosinophilic pleural effusions. Chest 1993;103:475–478.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.